PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

Clinical trial NCT00679835 · COMPLETED

Trial details

NCT number: NCT00679835
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Gram Positive Infection Concurrent Antibiotic Treatment

Start date: 2008-06-03
Primary completion: 2008-11-20
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.